Trials / Completed
CompletedNCT00725478
SEDPARK1: Safety and Efficacy Study With the Non-ergot Dopamine-agonist Piribedil in Parkinson's Disease
Stabilization on, or Change-over to the Non-ergot Dopamine Agonist Piribedil in Patients With Morbus Parkinson - a Post Marketing Surveillance Study in Parkinson Clinic Ambulances and Larger Private Practices.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 250 (actual)
- Sponsor
- Desitin Arzneimittel GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the non-interventional Post Marketing Study is to investigate the use of the non-ergot dopamine agonist piribedil (trade name: CLARIUM) in mono- and combination therapy in patients with Morbus Parkinson. Tolerability and course of the disease or change of parkinsonian symptoms during stabilisation on, or change over from other dopamine agonists will be documented under routine conditions. Piribedil should be prescribed according to its marketing authorisation by the responsible neurologist.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Piribedil |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2008-07-30
- Last updated
- 2010-03-31
Source: ClinicalTrials.gov record NCT00725478. Inclusion in this directory is not an endorsement.